Rn624, ri624    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
226間質性膀胱炎(ハンナ型)6

226. 間質性膀胱炎(ハンナ型) [臨床試験数:133,薬物数:151(DrugBank:46),標的遺伝子数:48,標的パスウェイ数:137
Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 133 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-014597-17-SE
(EUCTR)
03/05/201028/10/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2BFinland;Spain;Belgium;Germany;Sweden
2EUCTR2009-014597-17-FI
(EUCTR)
24/03/201004/12/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2BFinland;Germany;Belgium;Spain;Sweden
3EUCTR2009-014597-17-DE
(EUCTR)
19/03/201003/12/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2BFinland;Germany;Belgium;Spain;Sweden
4EUCTR2009-014597-17-ES
(EUCTR)
08/02/201012/11/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer, S.A.NULLNot RecruitingFemale: yes
Male: yes
300Phase 2BFinland;Belgium;Spain;Germany;Sweden
5EUCTR2009-014597-17-SK
(EUCTR)
03/02/201011/02/2010A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Slovakia;Finland;Spain;Belgium;Germany;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2009-014597-17-BE
(EUCTR)
24/12/200909/11/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 2BFinland;Germany;Belgium;Spain;Sweden